Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: Preliminary report of a phase II study

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Alongi, Filippo ^a   Cozzi, Luca ^b   Arcangeli, Stefano ^a   Iftode, Cristina ^a   Comito, Tiziana ^a   Villa, Elisa ^a   Lobefalo, Francesca ^a   Navarria, Pierina ^a   Reggiori, Giacomo ^a   Mancosu, Pietro ^a   Clerici, Elena ^a   Fogliata, Antonella ^b   Tomatis, Stefano ^a   Taverna, Gianluigi ^a   Graziotti, Pierpaolo ^a   Scorsetti, Marta ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Prostate; RapidArc; Stereotactic body radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL STUDY; FEASIBILITY STUDY; FILTER; FOLLOW UP; FREE FLATTENED FILTER; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LINEAR ACCELERATOR; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTON; PILOT STUDY; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT DURATION; URINE RETENTION; VOLUMETRIC MODULATED ARC THERAPY; ADENOCARCINOMA; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE FRACTIONATION; RADIOSURGERY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84879818128     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-171     Document Type: Article

References (23)

1. Arcangeli S, Scorsetti M, Alongi F. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol. 2012, 84:101-108. 10.1016/j.critrevonc.2011.11.009, 22257653.
2. Scorsetti M, Alongi F, Castiglioni S, et al. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol 2011, 6:113. 10.1186/1748-717X-6-113, 3179946, 21910868.
3. Weber DC, Zilli T, Vallee JP, et al. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylene glycol spacer: a treatment planning comparison study. Int J Radiat Oncol Biol Phys 2012, 84:e311-e318. 10.1016/j.ijrobp.2012.03.028, 22999271.
4. Song D, Herfarth K, Matthias U, et al. A Multi-institutional Clinical Trial of Rectal Dose Reduction via Injected Polyethylene-Glycol Hydrogel During Intensity Modulated Radiation Therapy for Prostate Cancer: Analysis of Dosimetric Outcomes. Int J Radiat Oncol Biol Phys 2013, in press.
5. Zeng GG, McGowan TS, Larsen TM, et al. Calcifications are potential surrogates for prostate localization in image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:963-966. 10.1016/j.ijrobp.2008.07.021, 18954708.
6. Lukka H, Hayter C, Julian JA, et al. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138. 10.1200/JCO.2005.06.153, 16135479.
7. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1. 10.1186/1471-2490-10-1, 2831888, 20122161.
8. Katz AJ, Santoro M, Di Blasio F, et al. Stereotactic body radiation therapy for low, intermediate and high-risk prostate cancer: disease control and quality of life. Int J Radiat Oncol Biol Phys 2011, 81:S100.
9. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3. 10.1186/1748-717X-6-3, 3022740, 21219625.
10. McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012, 118:3681-3690. 10.1002/cncr.26699, 22170628.
11. Fuller DB, Shirazi R, Naitoh J, et al. Virtual HDR SBRT For Localized Prostatic Carcinoma: Efficacy And Quality Of Life Assessment. Int J Radiat Oncol Biol Phys 2011, 81:S423-S424.
12. Kang JK, Cho CK, Choi CW, et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011, 97:43-48.
13. King CR, Brooks JD, Gill H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiation Oncology Biol Phys 2012, 82:877-882.
14. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105. 10.1016/j.ijrobp.2006.10.050, 17336216.
15. Boike TP, Lotan Y, Cho LC, et al. Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. J Clin Oncol 2011, 29:2020-2026. 10.1200/JCO.2010.31.4377, 3138546, 21464418.
16. Ritter MA, Forman JD, Kupelian P, et al. Five-year efficacy and toxicity outcomes from phase I/II trial of increasingly hypofractionated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2001, 81(S2):S99.
17. Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81:1271-1278. 10.1016/j.ijrobp.2010.07.1984, 20934277.
18. Pollack AW, Buyounouski M, Horwitz E, et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81(suppl):S1.
19. Kuban DA, Nogueras-Gonzalez NG, Hamblin L, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010, 78(suppl):S58.
20. Arcangeli S, Strigari L, Gomellini S, et al. Updated results and pattern of failures in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 84:1172-1178. 10.1016/j.ijrobp.2012.02.049, 22537541.
21. Dearnaley D, Syndicus I, Sumo G, et al. Conventional versus hypofractionated high dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from CHHiP randomized controlled trial. Lancet Oncol 2012, 13:4354.
22. Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiation Oncology Biol Phys 2011, 79:1013-1021.
23. Michalski JM, Gay H, Jackson A, et al. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S123-S129. 3319467, 20171506.